Epirubicin
Biopsy-proven, Positive Lymph Node(s)
Laura M. Spring, MDPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
6 Active assets in the Biopsy-proven, Positive Lymph Node(s) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Inno-206 Laura M. Spring, MD | Phase 3 | BB |
Cyclophosphamide Laura M. Spring, MD | Phase 3 | BB |
Eloxatin Chengdu New Radiomedicine Technology Co. LTD. | Phase 2 | B |
Carboplatin Tang-Du Hospital | Phase 2 | CCC |
Pembrolizumab Laura M. Spring, MD | Phase 2 | CCC |
Capecitabine Laura M. Spring, MD | Phase 2 | CCC |
Same molecule, other indications
Epirubicin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →